News1

Samsung Bioepis and Teva are partnering to develop and commercialize two immune-disease biosimilars in the U.S., Europe, and Canada.

Daim Bio’s DM5167 has received FDA Fast Track designation for patients with advanced salivary gland cancer, supporting accelerated development of its selective PARP1 inhibitor in the U.S.

SK Bioscience marks two years since acquiring IDT Biologika, enhancing its global CDMO capabilities with its own vaccines.Two years after acquiring IDT Biologika, SK Bioscience has improved the German CDMO’s profitability and expanded joint global projects, while integrating its own vaccine production remains a key next step.

I-Mab Biologics will present clinical and preclinical data on IMB-101, a bispecific antibody being developed for hidradenitis suppurativa, at EADV 2026 in Vienna.

NIBEC is accelerating its push into Europe with MDR-certified regenerative biomaterials while exploring expanded partnerships with major global dental and implant companies.

Daewoong Pharm is expanding into healthcare data security by supplying hospitals and clinics with a distributed backup and recovery solution designed to protect critical medical data from cyberattacks.

A Korean real-world study found that switching bipolar disorder patients to lurasidone was associated with modest weight loss, improved depressive symptoms, and no reported serious adverse events over 16 weeks.

Celltrion is strengthening its direct-sales presence across Europe as Aptozma, Omlyclo, and Osenvilt secure major tenders in Norway, Finland, the Netherlands, and Denmark.

HanAll BioPharma is advancing an FcRn-targeting therapy designed to reduce disease-causing antibodies directly, potentially offering a new treatment approach for Graves’ disease patients in the U.S.

JLK has published research on a large-scale stroke imaging database containing more than 20,000 patients, aiming to use the data to validate AI solutions and strengthen clinical evidence.

A team of cardiology professors at Severance Cardiovascular Hospital published four research papers in NEJM over nine months.

Research shows patients with myasthenia gravis have a higher rate of prior autoimmune diseases than the general population.

SillaJen registers a domestic patent for technology that evades neutralizing antibodies of anti-cancer viruses.

Seers has registered a Korean patent for AI technology that analyzes a 30-second single-lead ECG to assess the likelihood of paroxysmal atrial fibrillation, potentially expanding wearable ECG technology from arrhythmia detection to risk prediction.